Compare Abbott Laboratories (ABT) vs Best Buy Co Inc (BBY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Best Buy Co Inc — how do they compare? Abbott Laboratories trades at $95.61 (market cap $166.94B), while Best Buy Co Inc trades at $77.56 (market cap $16.59B). The key difference: Abbott Laboratories is far larger — about 10.1× Best Buy Co Inc's market cap, and Best Buy Co Inc pays the higher dividend (4.88%). Which is the better fit depends on your goals.
| ABT | BBY | |
|---|---|---|
Market Cap | $166.94B | $16.59B |
Sector | Health | Consumer Cyclical |
52-Week High | $136.62 | $84.00 |
52-Week Low | $82.57 | $55.52 |
Enterprise Value | $193.69B | $18.97B |
Dividend Yield | 2.63% | 4.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Best Buy (BBY) trades at $78.72, up 0.94% with a bullish technical outlook and positive earnings momentum after beating estimates for three consecutive quarters. The company shows strong profitability with 39.1% ROE and attractive valuation metrics including a 14.44 P/E ratio. Recent leadership transition and strategic focus on higher-margin businesses like marketplace expansion and retail media provide growth catalysts.
The stock offers value with a 5.11% dividend yield and 5% upside to consensus price target of $82.18, though revenue declines and competitive pressures in consumer electronics remain key risks. Analyst sentiment is mixed with 34% buy ratings versus 53% hold, reflecting cautious optimism about the turnaround strategy under new CEO Jason Bonfig.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Best Buy Co Inc
With $51.8 billion in fiscal 2022 sales, Best Buy is the largest pure-play consumer electronics retailer in the U.S., with roughly 10.6% share of the aggregate market and north of 40% share of offline sales, per our calculations, CTA industry, and Euromonitor data. The firm generates the bulk of its sales in-store, with mobile phones and tablets, computers, and appliances representing its three largest categories. Recent investments in e-commerce fulfillment, accelerated by the COVID-19 pandemic, have seen the U.S. e-commerce channel roughly double from prepandemic levels, with management estimating that it will represent a mid-30% proportion of sales moving forward.
Read more on BBY →
